Is the Novartis breakthrough gene therapy overpriced or not? – STAT
STAT |
Is the Novartis breakthrough gene therapy overpriced or not?
STAT ate last year, Novartis (NVS 1) began marketing a breakthrough gene therapy for treating youngsters with advanced leukemia and slapped a $475,000 price tag on the one-time treatment. The eye-popping number sparked debate, but the drug was quickly … |
